Pharmaceutical Companies– tag –
-
KRAS Special Series Part 6: Beyond Resistance — Wild-Type and Mutant RAS Co-Inhibition and the Dawn of Systems RAS Therapy
The rise of KRAS inhibitors marked the end of the “undruggable” era—but tumors adapt swiftly. Resistance often stems from a cooperative reactivation between mutant and wild-type RAS. This sixth installment dissects the molecular basis of... -
KRAS Special Series Part 5: The New Wave of KRAS Drug Discovery — Degraders, RAS(ON) Inhibitors, and AI-Driven Design
KRAS has evolved from the icon of “undruggable” to the engine of next-generation oncology. Building on the success of allele-selective inhibitors (e.g., G12C), the mid-2020s ushered in three powerful paradigms: RAS(ON) inhibition, pan-KR... -
KRAS Special Series Part 4: Immunity, Aging, and Regeneration — The Future of Life Regulation Through KRAS Signaling
KRAS research has now transcended oncology. Recent studies reveal that KRAS signaling interconnects with immunity, cellular aging, and even regenerative medicine. In this fourth installment, we redefine KRAS as a “life regulator” rather ... -
KRAS Special Series Part 3: The Silent Ally — How Wild-Type KRAS Builds Resistance Networks
As KRAS-targeted therapy enters a new era, one unexpected player has captured the spotlight: Wild-type KRAS (WT-KRAS). While mutant KRAS has long been seen as the dominant oncogenic driver, emerging evidence shows that its wild-type coun... -
KRAS Special Series Part 2: What Each Allele Tells Us — Biological and Clinical Diversity of G12D, G12V, G12R, and Q61
In Part 1, we traced the long struggle to target KRAS and the breakthrough that made the “undruggable” druggable. Now we turn to a crucial question: how do different KRAS alleles shape tumor biology, signaling behavior, and clinical outc... -
KRAS Special Series Part 1: The Rise, Fall, and Rebirth of the “Undruggable” Target
Few oncogenes have shaped the landscape of cancer research as profoundly as KRAS. Since the first RAS mutation was identified in human bladder cancer cells in 1982, this small GTP-binding protein has fascinated scientists as both a myste... -
Part 2｜Inside AMPLIFY-201 Final Analysis: What the KRAS Vaccine Is Actually Moving
Takeaway: Lymph-node–targeted amphiphile delivery achieved robust dual CD4/CD8 responses. A data-driven ~9.17× immune threshold aligned with RFS/OS gains and ctDNA negativity in the adjuvant MRD setting. Contents 1. One-Minute Summary 2.... -
[2025 Oct] KRAS Cancer Vaccine Competitive Map｜Elicio, SLATE-KRAS & Academic SLP Compared (Adjuvant MRD × Off-the-Shelf Era)
Takeaway: the field is coalescing around shared neoantigens × off-the-shelf × adjuvant MRD. Elicio (ELI-002 7P) leads the pack; academic SLP + poly-ICLC programs and Gritstone’s SLATE-KRAS follow. With V941 halted, the landscape is clear... -
UK Series (Final): Case Studies: Execution from the UK in Practice (3–5 Short Cases)
Executive Summary｜This collection grounds Parts 1–4 in practice: a rare-disease PoC, a multi-ancestry stratified trial, access optimization, manufacturing × capital structuring, and a repurposing example. Each case includes a ready-to-u... -
UK Series (Part 4): Execution from the UK: Trials, Access, and Manufacturing Playbooks
Executive Summary｜This playbook turns designs into action. By running regulation (MHRA), access (NICE), manufacturing, and commercial readiness in parallel, teams can compress time-to-market. We outline UK-led PoC timelines, parallel re... -
UK Series (Part 3): From Genomes to Targets: Biomarkers, Stratification, and Repurposing at Scale
Executive Summary｜UK-scale WGS and multi-ancestry GWAS enable earlier, stronger target validation, biomarker design, indication shaping, and safety anticipation. This article turns discoveries into practice—workflows, metrics, QC, and p... -
UK Series (Part 2): Data-Driven UK: How WGS and Multi-Ancestry GWAS Rewire Drug Discovery
Executive Summary｜The UK’s edge lies in its public data infrastructure. With ~490k whole-genome sequences (WGS) extending into non-coding, rare variants, and structural variation—and a multi-ancestry GWAS program (Pan-UK Biobank)—the ec... -
UK Series (Part 1): The UK Life Sciences Strategy: Policy, Regulation, and Investment at Full Tilt
Executive Summary｜The UK’s 2025 industrial strategy update places life sciences among its priority sectors, aiming to become Europe’s No.1 by 2030 and the world’s No.3 by 2035. In lockstep with the NHS long-term roadmap, the plan combin... -
Oncology Drug Approval News Flash: FDA Approves Lurbinectedin Plus Atezolizumab for Maintenance in Extensive-Stage Small Cell Lung Cancer
On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals) in combination with atezolizumab (Tecentriq, Genentech) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) fo... -
Bonus Track Special: Implications for Japan & Asia — How US “Reallocation” Reshapes Opportunities
Category: Pharma & Biotech NEWS | Special Feature B Key Takeaways Capital follows the cleared path (POC → CMC → access): US selectivity raises the bar for Asia-origin programs on speed, manufacturability, and reimbursement narrative.... -
Bonus Track-Special: Redesigning M&A & Partnerships — From Overlap Removal to “Rights Architecture”
Category: Pharma & Biotech NEWS | Special Feature A Key Takeaways PMI defines value: 80% of deal value crystallizes within 90–180 days post-close through speed and transparency; eliminate overlaps with KPI governance. Rights redesign... -
Series “Reading 2025 Layoffs” — Final: Practical Playbook: Checklists and Capital Strategy for Founders & Investors (Part 5)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 5 (Final) Key Takeaways Event-synced planning: script data (BM → topline) and financing (FPO/debt/partnerships) to minimize dilution. Shortest path to POC: focus ... -
Series “Reading 2025 Layoffs”: The Funding Climate: How Selectivity Works Across VC, Public, Debt, and M&A (Part 4)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 4 Key Takeaways Capital concentrates near POC: late-stage/near-commercial assets attract flows; discovery–preclinical is tightly screened; non-dilutive capital br... -
Series “Reading 2025 Layoffs”: Modality-by-Modality: Manufacturing, Regulatory, and Commercial Realities (Part 3)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 3 Key Takeaways The “capital-efficiency equation” is modality-specific: even with similar P2 wins, cell/gene/RNA/antibody–degrader programs require very different... -
Series “Reading 2025 Layoffs”: Reshaping by Disease Areas: From Oncology to Neuroscience (Part 2)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 2 Key Takeaways Oncology leads the reallocation: Cell therapies and solid tumors force a focus on indication picking, manufacturability, and reimbursement realism...
